Malignant transformation is a multistep process that is dictated by the acquisition of multiple genomic aberrations that provide growth and survival advantage. During the post genomic era, high throughput genomic sequencing has advanced exponentially, leading to identification of countless cancer associated mutations with potential for targeted therapy. Mouse models of cancer serve as excellent tools to examine the functionality of gene mutations and their contribution to the malignant process. However, it remains unclear whether the genetic events that occur during transformation are similar in mice and humans. To address that, we chose several transgenic mouse models of hematopoietic malignancies and identified acquired mutations in these mice by means of targeted re-sequencing of known cancer-associated genes as well as whole exome sequencing. We found that mutations that are typically found in acute myeloid leukemia or T cell acute lymphoblastic leukemia patients are also common in mouse models of the respective disease. Moreover, we found that the most frequent mutations found in a mouse model of lymphoma occur in a set of epigenetic modifier genes, implicating this pathway in the generation of lymphoma. These results demonstrate that genetically engineered mouse models (GEMM) mimic the genetic evolution of human cancer and serve as excellent platforms for target discovery and validation.
| I N T R O D U C T I O N
Genetically engineered animal models of human cancer have proven to be useful tools for investigating cancer initiation, progression, and therapy. [1] [2] [3] A common strategy employed in these studies is to generate mice that have one or more defined mutation(s) in the germline, and observe these mice for the onset of cancer over a defined study period.
In these experiments, it is anticipated that the mutation(s) engineered into the germline have disrupted one or more critical pathways required for malignant transformation, and that complementary pathways will become activated with time, possibly because of spontaneous somatic mutations. The fact that additional mutations can collaborate with transgenes to induce malignant transformation has been shown by acceleration of disease onset in transgenic mice through the use of mutagens such as N-ethyl-N-nitrosourea (ENU) or retroviral insertions. 4, 5 Investigators have traditionally used two approaches to identify genes and/or pathways that can complement a genetically engineered mutation. A targeted or candidate gene approach studies a limited number of genes that are known or suspected to be involved in malignant transformation, using PCR amplification and Sanger sequencing of target genes. Using this strategy, we have previously identified spontaneous mutations in one third of the leukemias that arose in NUP98-HOXD13 transgenic mice. 6, 7 These mutations most commonly involved
Ras pathway genes, such as Nras, Kras, Ptpn11, and Cbl. A major limitation of this strategy however is that novel gene mutations would not be identified, as only a limited number of genes is assayed.
An alternate approach involves mutagenizing the genome, and allowing for biological selection to identify a malignant clone. One limitation of this approach is that it does not necessarily mimic malignancies that arise spontaneously, in that the complementary mutations are forced using chemicals or retroviral insertions. However, this approach has clearly been successful, as chemical mutagenesis screens implicated APC as a critical gene involved in colon cancer, 8 and retroviral
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insertional mutagenesis identified Hoxa9, Meis1, Nf1, and Evi1 as genes important for leukemic transformation. [9] [10] [11] Over the past decade, whole genome sequencing (WGS) has emerged as a major tool for surveying the entire genome in order to identify cancer associated mutations. A complementary method, whole exome sequencing (WES), sequences only the exonic portion of the genome (3%); these two techniques have revolutionized the search for mutations in cancer genomes. [12] [13] [14] The ability of genetically engineered mice to accurately model human malignancy has been hotly debated. 1 In this study we used several transgenic mouse models of hematologic malignancies and examined the genetic events that occur during the generation of the disease by targeted sequencing and WES. We studied two different murine models of leukemogenic NUP98 fusions, NUP98-HOXD13 and NUP98-PHF23 that were established in our lab. 15, 16 Although NUP98 fusions have been considered rare events in patients with AML, recent studies
show that NUP98 fusions are present in approximately 5% of all pediatric AML patients, and as many as 15% of "normal karyotype" pediatric AML patients. [17] [18] [19] [20] A third murine model of AML that we studied was generated by expression of a CALM-AF10 transgene. 21 CALM-AF10 fusions are associated with AML and immature T-ALL in humans; the AML in both human patients and engineered murine models are characterized by clonal rearrangements of both IG and TCR genes, [22] [23] [24] suggesting that the cell of origin is multipotent. Both NUP98 fusions, which have recently been shown to be dependent on MLL1 for leukemic transformation, 25 as well as CALM-AF10 fusions lead to overexpression of HOXA7/9/10 (referred to as a "HOXA" cluster), which is thought to be a final common pathway leading to poor prognosis AML in both humans and mice. 18, 23, 26, 27 To broaden the models of hematopoietic malignancy evaluated, we studied a murine model of peripheral T cell lymphoma, not otherwise specified (PTCL-NOS) that was induced by overexpression of Lin28b. 28 Overexpression of LIN28B, or the closely related LIN28A, is seen in over 50% of patients with PTCL-NOS. 28 In this report, we show that certain gene mutations are highly recurrent in both human and mouse leukemia, validating that these mouse models are relevant to the human disease. These results also provide insight into gene pathways that are recurrently involved in specific malignancies and may serve as attractive targets for therapeutics.
| M E T H O D S

| Genetically engineered mouse models (GEMMs)
Construction of transgenic mice expressing NUP98-HOXD13 (NHD13), NUP98-PHF23 (NP23), CALM-AF10 (CA10) and Lin28b and the diagnoses of malignancies that arise in these mice have been described elsewhere. The following filtering criteria were used for germline variation calls: (1) minimum read depth is 5; (2) minimum altered read number is 3; (3) minimum fraction of altered reads is 0.01; (4) impact is 'High' or 'Moderate'. The following filtering criteria were used for somatic variation calls: (1) minimum read depth is 5; (2) maximum altered read number in reference samples ('Normal') is 2 or maximum fraction of altered reads in reference samples ('Normal') is 0.01.
Additional filtering is described in the results.
| Validation of sequencing results
Genomic DNA from paired tumor-normal (tail or kidney) tissues was used to PCR amplify regions where variants were identified by targeted re-sequencing or WES. Amplicons were purified and Sanger sequenced at the NCI CCR genomics core. To validate expression of variants, RNA was extracted from tumor tissue using TRIzol reagent according to the manufacturer's guidelines (Ambion). cDNA was synthesized using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) and then PCR amplified and sequenced.
| R E S U LTS
| Targeted Resequencing of mouse hematologic malignancies identifies acquired mutations in genes commonly mutated in human cancer
We have previously characterized four GEMMs of hematologic malignancy that develop a wide spectrum of disease, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia T-ALL, B-cell acute lymphoblastic leukemia (B-ALL), and peripheral T-cell lymphoma (PTCL). 15, 16, 21, 28 These models include mice that express NHD13, NP23, CA10, or Lin28b (Supporting Information Table S1 ) transgenes driven by Vav1 regulatory elements, which directs lineage specific expression to the hematopoietic compartment. 33 We used targeted re-sequencing to search for spontaneous somatic mutations in a set of genes known to be recurrently mutated in hematologic cancers (Supporting Information Tables S2,   S3 ). and Notch1 ( Figure 1A , Supporting Information Table S4 ). Most of the mutations were similar to mutations previously identified in human leukemia. For instance, we found numerous mutations in both Kras and Nras at amino acid positions 12, 13, 61 and 63, which are frequently mutated in cancer patients and considered mutational hotspots. In most cases (12/18), the variant allele frequencies (VAF) of the ras mutations were close to or greater than 0.5, suggesting that this mutation is a relatively early event (Supporting Information Table S4 ). In addition, several samples had VAF >0.7, suggesting reduction to homozygosity in a tumor subclone. Conversely, most mice with mutations in Ptpn11, which encodes a phosphatase known to affect ras signaling, had a low VAF (<0.25), suggesting that the mutation was only present in a minor subclone (Supporting Information Table S4 ).
Targeted re-sequencing of only 24 genes identified spontaneous mutations in more than half of the T-ALL samples and almost half of the AML samples ( Figure 1A ). The most common acquired mutation in the T-ALL samples involved the heterodimerization (HD) or proline, glutamic acid, serine, threonine-rich (PEST) domain of Notch1 ( Figure 1B ), similar to findings in human patients with T-ALL. 36 In contrast, the most common acquired mutations identified in the murine AML samples involved Ras or tyrosine kinase signaling pathways, similar to findings in human AML in general, 37 as well as NUP98-rearranged AML specifically. 17, 19, 20, 38 We have previously shown that Notch1 PEST domain mutations in murine primary pre-T LBL tumors have a high occurrence at two hot spots; R2361 and S2398. 39 Six of the 14 Notch1 PEST domain mutants identified in this screen mapped to one of those two "hotspots" for mutation.
Although we identified recurrent missense mutations and one in frame deletion in the Flt3 kinase domain (KD), we identified no internal tandem duplication (ITD) mutations in mouse AML samples using this multiplex PCR/next-gen sequencing approach. However, Flt3-ITD mutations were previously identified in two CA10 mice. 6 One of these mice (#7468) was included in this study, however, the assay did not detect the previously documented 39 bp insertion, suggesting that this assay may have missed large indels in Flt3. Therefore, to determine if these large insertions might have been missed due to alignment errors, we analyzed 22 NP23 AML samples for Flt3-ITD mutations using PCR primers that flank the previously identified murine Flt3-ITD (primers muFlt3LM For and muFlt3LM Rev 6 ) and found no ITD mutations (data not shown).
Mutations in epigenetic modifier genes, which are frequently found in AML patients 40 were typically absent from the mouse leukemias, with the exception of mutations in Idh1 (Supporting Information Figure 2A , Supporting Information Table   S4 ). Using an allele specific PCR assay, we were able to confirm that the Idh1 R132G mutation was present in two of these samples (1138, 2420, Figure 2B) ; we suspect the frequency of the Idh1 mutation in sample 1155 was below the level of detection of the assay. Table S1 ). Of note, only 2 out of 31 Lin28b
samples contained a mutation in any of the target genes, suggesting that the selected target genes were not common targets for the Lin28b PTCL model, indicating a need for an un-biased approach to unravel the mutational processes in these malignancies. Therefore, we performed whole exome sequencing (WES) on 17 Lin28b PTCL samples and 18 AML samples from NP23 mice in order to gain new insights into the genetic events leading to these malignancies. These results were analyzed using the approach summarized in Figure 3A .
Tier 1 variants were defined as non-synonymous mutations in coding regions with a VAF of >0.25 compared to a WT sibling. Figure 3B shows that the distribution of Tier I variants in NP23 and Lin28b tumors is very similar, with the median number of variants per sample being 13 for Lin28b and 10 for NP23. These values are similar to those in clinical series of WES for patients with AML or PTCL. 12, 44 Using this approach, we identified 40 recurrent variants; 18 in Lin28b and 22 in NP23 samples, respectively (Supporting Information Table S5 ).
Since our study was based on inbred mice, we initially assumed, as have others, 45 that germline mutations would be filtered out by our analysis. However, for 28 of the 40 recurrent variants, identical SNVs were documented in several samples (Supporting Information Table   S6 ). We suspected that these may be germline mutations and selected seven of the most common SNVs to validate by Sanger sequencing of Table S6 ). All of the mutations presented in Figure 5 and Table 1 Given that the stated criteria of VAF > 0. 25 Tables S8 and S9 ). Of these, a total of 12 non-coding SNVs were recurrent, identified in 2-13 samples.
However, these SNVs were precisely identical across the samples and, similar to the identical coding SNVs we identified, are suspected to be germline mutations within the colony (Supporting Information Tables   S8 and S9 ).
Acquired mutations in both models could be placed into several large functional categories (Table 1) . Within the Lin28b cohort, a large group of mutations were found in epigenetic regulators, similar to findings in lymphoma patients. 46 In some cases, we found these mutations to occur at the same position as ones previously reported in human malignancy, such as in Hist1h3b, Hist1h3d, and Asxl1 genes, while other mutations affected different residues within the same functional domains as seen in human malignancy (Table 1) . It should be noted that the Hist1h3b and Hist1h3d mutations occur at an amino acid residue (K27) well-known to be a critical residue for epigenetic regulation of transcription. 47 The Asxl1 frameshift mutation was because of an expansion of a G repeat tract (Supporting Information Figure S1 ); this form of mutation (addition of a G within a G repeat tract encoding a frameshift at codon 642) is the single most common ASXL1 mutation in MDS and AML patients. 48, 49 According to our study, one Lin28b-driven PTCL sample had acquired a nonsense mutation (Q516*) in Crebbp ( In summary, using targeted re-sequencing and whole exome sequencing, we identified and validated acquired mutations in 37 genes ( Figure 5 ). Examination of the recurrent mutations revealed that some events were unique to a specific type of malignancy. This implies that such mutations collaborate with the transgene to drive leukemia/lymphoma in a specific cell context.
| DISCUSSION
We studied collaborative mutations using mouse models of hematologic malignancies in which a single genetic aberration is introduced in the mouse germline and spontaneous, complementary mutations accumulate over time to generate a malignancy. 15, 21, 28, 39 It seems feasible that the disease latency reflects the mutational processes required to generate cancer-the stronger the driver mutation is, the fewer additional mutations are needed and the shorter the disease latency will be.
Of note, NUP98 fusions are likely to be early, initiating events in human AML, 20 similar to murine models in which transgenes engineered into the murine germline are initiating events.
We used targeted resequencing of selected candidate genes and WES to identify spontaneous, acquired mutations in murine hematopoietic malignancies. An important observation of this study is that, similar to findings in human patients, specific mutations are recurrently found in specific types of mouse leukemia and lymphoma ( Figure 5 ).
For instance, the most frequent mutation we identified in mouse T-ALL involved Notch1 ( Figure 1 ); 14 of 27 T-ALL cases had Notch1 mutations in the HD or PEST domains (Supporting Information Table S4 ). Similarly, over half of T-ALL patients carry activating mutations in Notch1, 36 indicating that Notch1 is a major driver of both human and mouse T-ALL. Interestingly, we found a Notch1 PEST domain mutation in a CALM-AF10 AML sample (Supporting Information Table S4 ) that had a clonal rearrangement of the Tcrb and Igh loci, 21 suggesting that this leukemia may have emerged from an immature and uncommitted progenitor cell.
A working hypothesis for collaborative mutations in AML suggests that myeloid leukemias have at least two complementary mutations; a "Class I" mutation that regulates cell proliferation and/or survival, and a "Class II" mutation that impairs differentiation or increases stem cell self-renewal. 40, 52 Of note, most of the spontaneous somatic mutations identified by targeted re-sequencing in the current study are considered to be "Class I" mutations, such as those involving Ras and Flt3.
Conversely, "Class II" mutations, such as those involving Npm1, Runx1
and Cebpa, as well as mutations in key epigenetic modifiers such as and CEBPA. In addition, mutations in epigenetic modifiers, such as DNMT3A, TET2, ASXL1 and IDH1/2, as well as NPM1, are absent or rare in both human and murine NUP98-fusion AML. 17, 19, 20, 38 An important exception to the above observation is the recurrent Idh1 mutations in NHD13 AML samples (Figure 2 , Supporting Information Table S4 ). IDH genes are recurrently mutated in a wide variety of tumors, including glioblastoma multiforme and AML. 13, 54, 55 These recurrent mutations in IDH1/2 genes lead to hypermethylation of both cytosine residues and histone lysine residues accompanied by a block in differentiation. [56] [57] [58] In addition, IDH2 mutations are thought to be early, pre-leukemic events that lead to expansion of hematopoietic stem and progenitor cells. 43 Two NHD13-driven AML samples had clo- Table S4 ). The exclusivity of these mutational events suggests that NHD13 and mutant Idh1 may collaborate in leukemia initiation or maintenance.
FLT3 mutations are common in unselected AML patients, and were recently found to occur in 36-63% of NUP98-rearranged AML. 17, 20, 38 We found Flt3 mutations in the murine AML samples, but not the murine PTCLs. Interestingly, we found several missense mutations and one in-frame deletion in the TKD of Flt3, but no ITD mutations in this sample set. Of note, no ITD was identified in CA10 # 7468, a sample that we previously reported had a 39 bp Flt3-ITD identified by PCR amplification and Sanger sequencing. 6 This finding highlights a limitation of NGS in ascertainment of large indels. As mentioned above, although uncommon, Flt3-ITD mutations can be acquired in mice, 6 and a Flt3-ITD collaborates potently with NHD13 to cause leukemia in a murine model. 59 Although speculative, it may be that the murine Flt3 locus is less susceptible to ITD events than the human FLT3 locus.
In our WES studies, control DNA was obtained from wild type littermates of the inbred transgenic mice. This approach decreases the Table S6 ). Exceptions to this generalization were found in wellknown "hot spot" mutations of established cancer genes, such as Idh1, Flt3, Nras, and Kras. Acquired SNVs were previously noted within a colony of congenic mice that had been backcrossed 101 generations. 60 This and the current report highlight the importance of sequencing non-malignant tissue, even when studying inbred mice, in order to distinguish somatic mutations from germline mutations that can arise within a mouse colony. Of note, some germline mutations are associated with predisposition to cancer and may be functionally relevant. 61, 62 WES of murine Lin28b PTCL samples revealed recurrent mutations in genes that are involved in epigenetic regulation of transcription, such as Hist1h3b, Hist1h3d, Asxl1, Mll2, Dot1l, Ezh2, and Crebbp (Table   1 ). Mutations in epigenetic modifiers have been widely reported in patients with hematopoietic malignancies, and, in the case of Asxl1 and histone genes, are identical to those found in murine Lin28b PTCL. 48, 49, [63] [64] [65] In summary, parallels between the mutational evolution of mouse and human malignancies supports the sequencing of mouse tumors as a discovery tool for collaborative mutations relevant to human disease.
In this study, we identified at least one likely collaborative mutation in >60% of our samples. We have shown that several epigenetic factors are subject to mutation in Lin28b-driven PTCL, identifying them as candidate genes that may play a role in human PTCL. This important finding indicates that aberrant chromatin remodeling is a critical process during development of hematopoietic malignancies, and highlights epigenetic regulatory proteins as promising targets for therapeutic intervention.
